Evis Sala, Deputy Scientific Director at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, shared on LinkedIn:
“Live from the European Cancer Summit 2026 in Brussels, where I’ve just come out of a thought-provoking session. Four messages stayed with me:
We are measuring only the tip of the iceberg.
Cancer costs Europe an estimated €199 billion a year. Much of that sits outside the hospital in lost work, informal care from families and out-of-pocket spending, and payers rarely see it. One proposal I strongly support is a mandatory minimum dataset in cancer trials, covering ability to work, hours of informal care and household spending. Survival gains matter, and so does what they mean for people’s lives.
The gaps in high-value care are still wide.
OECD/EC data show that a third of lung cancers are diagnosed through the emergency department. Mortality after colorectal surgery varies five-fold across EU countries. Having served as Minister of Health of Albania until September, I know these gaps look different from the policy side. They are rarely about a lack of will. Far more often they come from fragmented data, disconnected pathways and short funding cycles. Care continuity is a data and governance problem as much as a clinical one.
Risk-adapted screening is where precision meets value.
The prostate cancer evidence was compelling. A risk-stratified pathway runs from risk assessment to PSA and biomarkers, then MRI, then targeted biopsy. It reduces both overdiagnosis and metastatic disease. More than 80% of men with a low baseline PSA at 50 are at low risk and can be screened far less often. MRI adds value but also drives cost. For radiology, the challenge is clear:
- abbreviated protocols
- AI-supported reading
- structured reporting
can make imaging-led screening both effective and affordable.
The returns are real, but only with sustained investment.
The European Cancer Organisation’s new study found measurable human and economic returns in all nine areas of cancer control it examined. These returns go well beyond health: costs avoided, productivity preserved and stronger health systems. But they depend on sustained, predictable funding that turns pilots into national practice, often over years or decades. The proposed 2028–2034 MFF would end EU4Health with no ring-fenced health budget, while many Beating Cancer Plan actions run to 2030. Scaling back now would mean giving up returns already within reach, for member states and for candidate countries working to align with them.
The common thread is to make the invisible visible and keep investing. That means patient-relevant outcomes, real-world costs, the data infrastructure to capture them, and the funding to see it through.
Thank you to the European Cancer Organisation for a session that connected economics, health systems and clinical evidence.
Proud to represent the radiology community!”
You may also be interested in:
Evis Sala: Four Key Reflections From the AI in Health Summit 2026
Is Europe Ready to Make Cancer a Funding Priority? – European Cancer Organisation